Clinical Trial Update: Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer [Phase 3]

View source ↗

Summary

Pfizer-sponsored Phase 3 trial evaluating figitumumab (CP-751,871) with erlotinib in refractory lung cancer was terminated and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenosquamous Carcinoma of the Lung
• Large Cell Lung Carcinoma
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Figitumumab (figitumumab)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED | Results posted: 2013-07-24